1-8 of 8
Martin Hofmann
Close
Sort by
Journal Articles

IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME

Sebastian Bunk, Martin Hofmann, Gabriele Pszolla, Meike Hutt, Frank Schwöbel, Felix Unverdorben, Nadine Aschmoneit, Claudia Wagner, Maike Jaworski, Heiko Schuster, Florian Schwoerer, Christoph Schraeder, Oliver Schoor, Sarah Missel, Toni Weinschenk, Dominik Maurer, Carsten Reinhardt
Journal: Blood
Blood (2022) 140 (Supplement 1): 9089–9090.
https://doi.org/10.1182/blood-2022-165937
Published: 2022
Journal Articles

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Sebastian Bunk, PhD, Martin Hofmann, PhD, Felix Unverdorben, PhD, Meike Hutt, PhD, Gabriele Pszolla, PhD, Frank Schwöbel, PhD, Claudia Wagner, PhD, Sara Yousef, PhD, Heiko Schuster, PhD, Sarah Missel, PhD, Oliver Schoor, PhD, Toni Weinschenk, PhD, Harpreet Singh-Jasuja, PhD, Dominik Maurer, PhD, Carsten Reinhardt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3368.
https://doi.org/10.1182/blood-2019-129958
Published: 2019
Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD
Journal: Blood
Blood (2013) 122 (21): 1454.
https://doi.org/10.1182/blood.V122.21.1454.1454
Published: 2013
Journal Articles

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

Ursula J.E. Seidel, Ludger Grosse-Hovest, PhD, Patrick Schlegel, MD, Martin Hofmann, Friedhelm R. Schuster, MD, Kai-Erik Witte, Steffen Aulwurm, PhD, Rouwen Teltschik, Elwira Pyz, PhD, Hans-Georg Rammensee, Gundram Jung, MD, Rupert Handgretinger, Prof., Peter Lang, MD
Journal: Blood
Blood (2013) 122 (21): 3905.
https://doi.org/10.1182/blood.V122.21.3905.3905
Published: 2013
Journal Articles

The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity

Carla E Schumacher, Tina Nuebling, PhD, Martin Hofmann, Benjamin J Schmiedel, PhD, Lothar Kanz, MD, Gundram Jung, MD, Helmut R Salih, MD
Journal: Blood
Blood (2012) 120 (21): 3548.
https://doi.org/10.1182/blood.V120.21.3548.3548
Published: 2012
Journal Articles

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Peter Lang, MD, Heiko-Manuel Teltschik, MD, Patrick Schlegel, MD, Ursula Seidel, Ludger Grosse-Hovest, PhD, Steffen Aulwurm, PhD, Martin Hofmann, Rouwen Teltschik, Kai Witte, MD, Hans-Georg Rammensee, Prof., Gundram Jung, MD, Rupert Handgretinger, MD
Journal: Blood
Blood (2012) 120 (21): 581.
https://doi.org/10.1182/blood.V120.21.581.581
Published: 2012
Journal Articles

Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies

Kristina Nalivaiko, Martin Hofmann, Ludger Grosse-Hovest, Peter H Krammer, Hans-Georg Rammensee, Helmut R. Salih, MD, Gundram Jung
Journal: Blood
Blood (2011) 118 (21): 1114.
https://doi.org/10.1182/blood.V118.21.1114.1114
Published: 2011
Journal Articles

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Helmut R. Salih, MD, Tina Baessler, Martin Hofmann, Ludger Grosse-Hovest, Maximilian Bamberg, Steffen Aulwurm, Hans-Joerg Buehring, Lothar Kanz, MD, Gundram Jung
Journal: Blood
Blood (2010) 116 (21): 2187.
https://doi.org/10.1182/blood.V116.21.2187.2187
Published: 2010